Forziga 5mg (14 Tablet / Pack)
A targeted low-dose oral SGLT2 inhibitor for blood glucose management and cardiac support.
Forziga 5mg Tablets are a lower initiation or maintenance dose of a selective SGLT2 inhibitor designed to safely optimize glycemic control in adult patients with Type 2 Diabetes. By facilitating controlled renal glucose clearance, it aids in reducing blood sugar spikes, supporting weight management, and providing crucial physiological protection against chronic heart failure progression.
Purpose
Promotes glucose excretion through the kidneys to reduce circulating blood sugar levels and alleviate systemic fluid strain.
Ingredients
Dapagliflozin 5mg
Warnings
Utilize strictly as an auxiliary adjunct to a structured, clinician-approved dietary framework and regular physical exercise. Patients presenting with severe, advanced chronic kidney disease may experience reduced glycemic therapeutic efficacy. Check blood glucose levels regularly if co-prescribed with insulin or sulfonylureas to prevent unexpected hypoglycemia. Stop administration and report to a doctor if you develop a severe, high-grade fever accompanied by localized perineal pain.
Side Effects
Mildly increased urge to urinate or minor nocturnal polyuria. Low-grade localized skin itching or minor fungal irritation in genital zones. Transient mild dry mouth or a slight increase in daily fluid intake requirements. Occasional low-grade back pain or minor musculoskeletal discomfort.
Storage Instructions
Store below 25°C in a cool, dry environment, shielding the blister sheets from extreme ambient heat.
| Status | Active |